NEW YORK, Jan. 31, 2022 /PRNewswire/ -- The global phenylketonuria treatment market is dominated by North America. The incidence of the condition is increasing in newborns in the region. This is increasing the focus on phenylketonuria treatment research, which has created opportunities for the vendors of products related to phenylketonuria treatment.
The region is also home to many leading players such as Abbott Laboratories, Prinova Group LLC., Aegle Nutrition, Archer Daniels Midland Company, ABCO Laboratories, Inc., and others which is further contributing to the growth of the regional market.
To understand more about Market Dynamics. Download our FREE sample report
Key Phenylketonuria treatment Market Report Highlights:
Regional Market Analysis
Although 34% of the growth is expected to originate from North America, this region will record a slower growth rate during 2021-2026. Increasing research studies and ongoing clinical trials of new drugs will significantly contribute to the growth of the phenylketonuria market in North America. Also, increasing government support for clinical research on phenylketonuria will foster the growth of the regional market.
The market will observe a faster growth in Asia and Europe during the forecast period.
For Additional Information about the regional market: Request for a free sample report.
Phenylketonuria Treatment Market: Key Vendors and Vendor Strategies
The phenylketonuria treatment market is concentrated, and the degree of concentration will accelerate during the forecast period. American Gene Technologies, BioMarin Pharmaceutical Inc., Codexis Inc., Evox Therapeutics Ltd., Homology Medicines Inc., Jnana Therapeutics, SOM INNOVATION BIOTECH SA, and Synlogic Inc. are some of the major market participants.
The vendors in the market are constantly focusing on launching new products and engaging in M&A activities to remain competitive in the market.
American Gene Technologies: The company offers Phenylketonuria (PKU) cure program for the treatment of Phenylketonuria in adults.
BioMarin Pharmaceutical Inc.: The company offers PALYNZIQ which is a self-administered therapy that acts independently of the phenylalanine hydroxylase (PAH) enzyme, so it is an option for all eligible adult patients living with Phenylketonuria (PKU).
Codexis Inc.: The company offers CDX-6114, which is a potential oral enzyme for the therapy for PKU as treatment.
Evox Therapeutics Ltd.: The company offers treatment for Phenylketonuria (PKU) which is an autosomal recessive inborn error of phenylalanine metabolism resulting in a deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH).
Homology Medicines Inc.: The company offers HMI-102, HMI-103, and others for the treatment of Phenylketonuria (PKU) which is a rare inborn error of metabolism caused by a mutation in the PAH gene. PKU results in a loss of function of the enzyme phenylalanine hydroxylase, which is responsible for the metabolism of phenylalanine (Phe), an amino acid obtained exclusively from the diet.
Download our free sample report to get a brief understanding of various other vendors and their strategies.
Key Market Drivers
Our analysts have extensively outlined the information on the key market drivers and their impact on the phenylketonuria treatment market.
The development of various technologies in genetics has been attracting significant investments in genomic research. This is helping genomic research institutes and organizations to develop novel therapies and personalized drugs for targeted therapies and incurable diseases. For instance, in 2019, the Government of Canada announced its plans to support 36 genomic research projects by funding USD 22.7 million through Genome Canada. Similarly, In 2019, under its research and innovation program, Horizon 2020, the EU announced the launch of the European Advanced infrastructure for Innovative Genomics (EASI-Genomics) project with about USD 11.2 million. Many such investments in the field of genomics will positively influence the growth of the global phenylketonuria treatment market during the forecast period.
To know about a few other market drivers, trends, and challenges,
Download our free sample report
Related Reports:
Sickle Cell Disease Treatment Market by Indication and Geography - Forecast and Analysis 2021-2025
Cervical Dystonia Therapeutics Market by Product and Geography - Forecast and Analysis 2021-2025
Phenylketonuria Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 9.06% |
Market growth 2022-2026 |
USD 481.45 million |
Market structure |
Concentrated |
YoY growth (%) |
6.44 |
Regional analysis |
North America, Europe, Asia, and ROW |
Performing market contribution |
North America at 34% |
Key consumer countries |
US, Canada, Turkey, Ireland, UK, and Australia |
Competitive landscape |
Leading companies, competitive strategies, consumer engagement scope |
Companies profiled |
American Gene Technologies, BioMarin Pharmaceutical Inc., Codexis Inc., Evox Therapeutics Ltd., Homology Medicines Inc., Jnana Therapeutics, SOM INNOVATION BIOTECH SA, and Synlogic Inc. |
Market Dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and future consumer dynamics, market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/
SOURCE Technavio
Share this article